http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Han, Wonshik,Kang, So Young,Kang, Daehee,Park, Sue K,Lee, Ji-Young,Kim, Ho,Park, Ae Kyung,Noh, Dong-Young National Hellenic Research Foundation 2010 ONCOLOGY REPORTS Vol.23 No.3
<P>We sought to identify genes and polymorphisms associated with breast cancer risk among Korean women using multiplex genotyping. The SNPs (n=1536) of 264 candidate genes were genotyped using the Illumina Golden Gate assay. These genes are involved in the pathways controlling apoptosis/anti-apoptosis, the immune and inflammatory responses, cytokines, DNA repair, cell adhesion, and cell cycle/proliferation. Breast cancer cases (n=209) were recruited from Seoul National University Hospital. Age-matched control subjects (n=209) were selected from a health examinees cohort. Gene-based and SNP-based tests were performed. The final analysis includes 117 cases and 164 controls with 1107 SNPs in 232 genes. Gene-based analyses showed that IL1A, TNFRSF10B, TNFRSF1B, ICAM, and TNFSF9 were significantly associated with breast cancer risk (p<0.01). IL1A was the most significant gene associated with breast cancer risk [p for likelihood ratio test, 1 degree of freedom (df)=6x10(-7); FDR-adjusted p-value, 1df=4x10(-4), 2df=0.0071, respectively]. Individual SNP-based analyses revealed that the rare allele of the IL1A SNP rs2856836, Ex7-592Tright curved arrow C, was strongly associated with breast cancer risk (FDR-adjusted p-value, 1df=0.0027, 2df=0.0162). This SNP was found to increase risk for breast cancer [odds ratio (OR)=2.88, 95% confidence interval (CI)=1.58-5.27 for heterozygote and OR=8.17, 95% CI=2.23-29.99 for rare homozygote]. In summary, we identified a common genetic variant in IL1A strongly associated with breast cancer risk.</P>
Han, Sang-Ah,Kim, Sung-Won,Kang, Eunyoung,Park, Sue K,Ahn, Sei-Hyun,Lee, Min Hyuk,Nam, Seok-Jin,Han, Wonshik,Bae, Young Tae,Kim, Hyun-Ah,Cho, Young Up,Chang, Myung Chul,Paik, Nam Sun,Hwang, Ki-Tae,Kim Kluwer Academic Publishers 2013 Familial cancer Vol.12 No.1
<P>The primary aim of this study was to estimate the prevalence of BRCA1/2 mutations among familial breast cancer (BC) patients in Korea. We analyzed 775 familial BC patients who were enrolled in the Korean Hereditary Breast Cancer (KOHBRA) study and treated at 36 institutions between May 2007 and May 2010. Patients with familial BC were defined as BC patients with family histories of BC or ovarian cancer (OC) in any relatives. All probands received genetic counseling and BRCA genetic testing was performed after obtaining informed consent. The mean age of BC diagnosis was 43.6 years. The numbers of probands with family histories of BC only and OC only were 682 and 93, respectively. The overall prevalence of the BRCA mutation among familial BC patients was 21.7 % (BRCA1 9.3 % and BRCA2 12.4 %). Subgroup analyses observed prevalences of the BRCA mutation as follows: 19.6 % among patients with BC family history only (BRCA1 7.6 % and BRCA2 12.0 %) and 36.6 % among patients with OC family history only (BRCA1 21.5 % and BRCA2 15.1 %). Most of the subgroups satisfied the 10 % probability criteria to undergo BRCA testing. However, the prevalence of the BRCA mutations among subgroups that had 2 BC patients in a family with both age at diagnosis of more than 50 years old did not reach the 10 % criteria (4.1 %). Korean familial BC patients are good candidates for BRCA testing even when they have family histories of single breast cancers. However, proband age at diagnosis should be carefully considered when selecting patients for testing.</P>
Lee, Han-Byoel,Kang, Un-Beom,Moon, Hyeong-Gon,Lee, Jiwoo,Lee, Kyung-Min,Yi, Minju,Park, Yong Sun,Lee, Jong Won,Yu, Jong-Han,Choi, Seung Ho,Cho, Sang Heon,Lee, Cheolju,Han, Wonshik,Noh, Dong-Young Potamitis Press 2015 Anticancer research Vol.35 No.11
<P>We aimed to develop a plasma protein signature for breast cancer diagnosis by using multiple reaction monitoring (MRM)-based mass spectrometry.</P>
The Effect of Cold Ischemic Time on Immunohistochemical Evaluation of Invasive Ductal Carcinoma
Hye Jin Kim,Han-Byoel Lee,Tae-Kyung Yoo,Jongjin Kim,Young-Joon Kang,Jaihong Han,Yumi Kim,Hyeong-Gon Moon,Wonshik Han,Dong-Young Noh 한국유방암학회 2015 Journal of Breast Disease Vol.3 No.2
Purpose: Immunohistochemical (IHC) evaluation is important for the management of breast cancer. Cold ischemic time (CIT) may result in inaccurate IHC results. The aim of this study was to investigate the effect of CIT on IHC results of invasive ductal carcinoma (IDC). Methods: We retrospectively reviewed the records of 316 patients diagnosed with IDC from February 2013 to June 2013 at a single hospital in Korea. The clinicopathological characteristics and IHC positivity for the estrogen receptor (ER), progesterone receptor (PR), Ki-67, and human epidermal growth factor receptor 2 (HER2) were compared between specimens with a CIT of ≤3 hours (short CIT) and those with a CIT of >12 hours (long CIT). Results: Among the 316 patients, 227 had a CIT of ≤3 hours and 89 had a CIT of >12 hours. No difference in positivity for ER (p=0.734), PR (p=0.870), and HER2 (p=0.830) was observed between the two groups. In ER-positive specimens, the mean percentage value was higher in the long CIT group than in the short CIT group (81.3±20.8% vs. 76.0±26.3%, respectively; p=0.021). The mean Ki-67 value was higher in the long CIT group compared to the short CIT group (9.7±14.6% vs. 7.0±10.8%, respectively; p=0.047). Conclusion: CIT did not affect the positivity of ER, PR, HER2, and Ki-67 as determined by IHC when stored at 4°C overnight. However, specimens with a long CIT had a higher ER percentage value in ER-positive tumors and a higher Ki-67 value in all specimens compared to those with a short CIT. These differences should be considered in the interpretation of IHC results in specimens with a long CIT.